Curis falls on GDC-0449 update

Curis Inc. (NASDAQ:CRIS) fell $0.22 (13%) to $1.52 on Monday after receiving an update from partner Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit on a Phase II trial of GDC-0449 to treat ovarian cancer. Roche and Genentech said preliminary data from the trial "warrant additional investigation to clarify and interpret potential clinical activity" of GDC-0449. The pharma and its unit plan to analyze the data, including subset analyses, in the coming months before deciding whether they will continue development of GDC-0449 for the indication. The double-blind, placebo-controlled trial enrolled 104 ovarian cancer patients in second or third complete remission. GDC-0449 is a small molecule antagonist of the hedgehog pathway. ...